Certuity’s Protagonist Therapeutics PTGX Stock Holding History

Certuity’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,251	Closed	-$284K	–	693
2025 Q4	$284K	Sell	3,251 -1,284	-28%	-$105K	0.02%	435
2025 Q3	$301K	Buy	+4,535	New	+$258K	0.02%	394

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Certuity's PTGX Position: Q1 2026 in Review

Certuity sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 3,251 shares — an estimated $284K sold.

Certuity first reported a position in PTGX in Q3 2025 and held it in 2 quarters. The position peaked at $301K in Q3 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Certuity reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Certuity sold 3,251 Protagonist Therapeutics shares in Q1 2026, an estimated $284K.
Certuity first reported a position in Protagonist Therapeutics in Q3 2025 and held it in 2 quarters.
Certuity's Protagonist Therapeutics position peaked at $301K in Q3 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Certuity's 13F filing for Q1 2026, filed 11 May 2026.